HER2-Orientated Therapy in Early and Metastatic Breast Cancer

Publisher： Karger

E-ISSN： 1661-3805|11|6|392-397

ISSN： 1661-3791

Source： Breast Care, Vol.11, Iss.6, 2016-12, pp. : 392-397

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapy Standards in HER2-Positive Breast Cancer

By  

Breast Care, Vol. 11, Iss. 2, 2016-04 ,pp. : 148-150

Karger

Access to resources Recommend Favorite

Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer

By  

Breast Care, Vol. 11, Iss. 6, 2016-11 ,pp. : 418-422

Karger

Access to resources Recommend Favorite

Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel

By  

Breast Care, Vol. 11, Iss. 2, 2016-02 ,pp. : 133-138

Karger

Access to resources Recommend Favorite

Cytostatic Therapy in Metastatic Breast Cancer

By  

Breast Care, Vol. 1, Iss. 4, 2006-09 ,pp. : 256-258

Karger

Access to resources Recommend Favorite

Trastuzumab (Herceptin®): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation

By  

Breast Care, Vol. 1, Iss. 2, 2006-05 ,pp. : 78-84

Karger

Access to resources Recommend Favorite